PFE
Pfizer · Health Care
1.5%
typical move (median |reaction| of last 8)
2026-11-03 pre · likely
next expected · estimated from pattern
13
scored events
Last eight reactions
2024-10-29 → 2026-08-04
| date | session | reaction | |move| | excess 5s | excess 20s |
|---|---|---|---|---|---|
| 2026-08-04 | pre | +1.4% | 1.4% | +4.8% | +13.7% |
| 2026-05-05 | pre | +0.5% | 0.5% | -2.5% | -6.7% |
| 2026-02-03 | pre | -3.4% | 3.4% | +6.8% | +4.0% |
| 2025-11-04 | pre | -1.5% | 1.5% | +5.6% | +5.9% |
| 2025-08-05 | pre | +5.1% | 5.1% | -2.7% | -2.4% |
| 2025-04-29 | pre | +3.3% | 3.3% | -4.7% | -6.8% |
| 2025-02-04 | pre | -1.2% | 1.2% | -2.0% | +3.2% |
| 2024-10-29 | pre | -1.4% | 1.4% | -0.8% | -11.4% |
Source filings
2026-08-04 · 8-K press release
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance ■ Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products (1) ■ Advancing Robust Lat
2026-05-05 · 8-K press release
g Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance ■ Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products (1) ■ Pipeline Momentum Bui
2026-02-03 · 8-K press release
g Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance ■ Focused Execution Drives Strong Full-Year 2025 EPS Performance ■ Enters 2026 with Clear Strategic Priorities and Growing Lat
2025-11-04 · 8-K press release
g Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance ■ Focused Execution Delivers Strong EPS Performance ■ Landmark Agreement Reached with U.S. Government Provides L
2025-08-05 · 8-K press release
g Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance ■ Strengthened Commercial Execution Driving Topline Growth ■ Continued Progress Across R&D Pipeline ■ Expanded Programs
2025-04-29 · 8-K press release
g Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance ■ Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment ■ Made Significant Progress Strength
2025-02-04 · 8-K press release
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance ▪ Full-Year 2024 Revenues of $63.6 Billion, Reflecting 7% Year-over-Year Operational Growth – Excluding Contributions from Paxl
2024-10-29 · 8-K press release
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance ▪ Third-Quarter Performance Driven by Focused Commercial Execution and Robust Double-Digit Revenue Growth Across Product Portf